LSE - Delayed Quote USD

BioMarin Pharmaceutical Inc. (0HNC.L)

59.30

+0.44

+(0.75%)

At close: April 17 at 6:57:17 PM GMT+1

Why BioMarin Pharmaceutical (BMRN) is a Top Growth Stock for the Long-Term

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Zacks yesterday

BMRN
Bristol Myers Squibb (BMY) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

Bristol Myers (BMY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks 2 days ago

CELG-RT

BMRN
BioMarin to Host First Quarter 2025 Financial Results Conference Call and Webcast on Thursday, May 1, 2025, at 4:30pm ET

BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that Alexander Hardy, President and Chief Executive Officer of BioMarin, will host a conference call and webcast on Thursday, May 1, 2025, at 4:30 p.m. ET to discuss first quarter 2025 financial results and provide a general business update.

PR Newswire 2 days ago

BMRN
BioMarin Pharmaceutical (BMRN) Earnings Expected to Grow: What to Know Ahead of Q1 Release

BioMarin (BMRN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks 3 days ago

BMRN
Legend Biotech (LEGN) Moves 5.1% Higher: Will This Strength Last?

Legend Biotech (LEGN) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.

Zacks 3 days ago

LEGN

BMRN
Unpacking Q4 Earnings: AbbVie (NYSE:ABBV) In The Context Of Other Therapeutics Stocks

The end of the earnings season is always a good time to take a step back and see who shined (and who not so much). Let’s take a look at how therapeutics stocks fared in Q4, starting with AbbVie (NYSE:ABBV).

StockStory 3 days ago

ABBV

BMRN

MRNA
6 Stocks With Clear Price Dislocations That I Purchased During Wall Street's Historic Volatility

Though the stock market is still historically pricey, a few phenomenal bargains have cropped up.

Motley Fool 9 days ago

PFE

INTC

BMRN
Will BioMarin (BMRN) Beat Estimates Again in Its Next Earnings Report?

BioMarin (BMRN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Zacks 9 days ago

BMRN
Strength Seen in BioMarin (BMRN): Can Its 6.3% Jump Turn into More Strength?

BioMarin (BMRN) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.

Zacks 9 days ago

BMRN

MRUS
Astronics and Boston Beer have been highlighted as Zacks Bull and Bear of the Day

Astronics and Boston Beer have been highlighted as Zacks Bull and Bear of the Day.

Zacks 10 days ago

ATROB

BMRN

SAM
Will Trump Tariffs Make or Break Healthcare Space? 3 Stocks to Rely On

Investors looking to maintain exposure to healthcare can invest in large-cap U.S.-based companies like UHS, BMRN and ABT.

Zacks 10 days ago

UHS

BMRN

ABT
5 Biotech Stocks Worth Adding Amid Global Uncertainty in 2025

New drug approvals and encouraging pipeline progress should maintain momentum in the Zacks Biomedical and Genetics industry despite the uncertain macroeconomic environment. A strong portfolio and solid pipeline progress position GILD, BMRN, KRYS, ADMA and FOLD well in this volatile sector.

Zacks 12 days ago

BMRN

ADMA

KRYS
3 Reasons Why Growth Investors Shouldn't Overlook BioMarin (BMRN)

BioMarin (BMRN) possesses solid growth attributes, which could help it handily outperform the market.

Zacks 12 days ago

BMRN
What Makes BioMarin (BMRN) a New Buy Stock

BioMarin (BMRN) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Zacks 12 days ago

BMRN
BMRN vs. CSLLY: Which Stock Is the Better Value Option?

BMRN vs. CSLLY: Which Stock Is the Better Value Option?

Zacks 12 days ago

BMRN

CSL.AX
Are You a Value Investor? This 1 Stock Could Be the Perfect Pick

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Zacks 12 days ago

BMRN
Spotting Winners: United Therapeutics (NASDAQ:UTHR) And Therapeutics Stocks In Q4

As the craze of earnings season draws to a close, here’s a look back at some of the most exciting (and some less so) results from Q4. Today, we are looking at therapeutics stocks, starting with United Therapeutics (NASDAQ:UTHR).

StockStory 12 days ago

UTHR

BMRN

MRNA
BMRN's PKU Drug Palynziq Meets Goal in Late-Stage Pediatric Study

Based on the late-stage data, BioMarin plans to submit a regulatory filing for expanding the label of its PKU drug Palynziq in adolescents before this year's end.

Zacks 16 days ago

BMRN

CTMX
Q4 Earnings Outperformers: Amgen (NASDAQ:AMGN) And The Rest Of The Therapeutics Stocks

The end of the earnings season is always a good time to take a step back and see who shined (and who not so much). Let’s take a look at how therapeutics stocks fared in Q4, starting with Amgen (NASDAQ:AMGN).

StockStory 16 days ago

AMGN

BMRN

MRNA
BioMarin’s trial for phenylketonuria therapy meets primary efficacy endpoint

Later this year, the company plans to submit detailed outcomes from this trial to health authorities.

Clinical Trials Arena 16 days ago

BMRN

Performance Overview

Return	0HNC.L	MSCI WORLD (^990100-USD-STRD)
YTD	-10.17%	-6.25%
1-Year	-33.17%	+6.77%
3-Year	-27.04%	+16.08%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

BioMarin Pharmaceutical Inc. (0HNC.L)

Why BioMarin Pharmaceutical (BMRN) is a Top Growth Stock for the Long-Term

Bristol Myers Squibb (BMY) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

BioMarin to Host First Quarter 2025 Financial Results Conference Call and Webcast on Thursday, May 1, 2025, at 4:30pm ET

BioMarin Pharmaceutical (BMRN) Earnings Expected to Grow: What to Know Ahead of Q1 Release

Legend Biotech (LEGN) Moves 5.1% Higher: Will This Strength Last?

Unpacking Q4 Earnings: AbbVie (NYSE:ABBV) In The Context Of Other Therapeutics Stocks

6 Stocks With Clear Price Dislocations That I Purchased During Wall Street's Historic Volatility

Will BioMarin (BMRN) Beat Estimates Again in Its Next Earnings Report?

Strength Seen in BioMarin (BMRN): Can Its 6.3% Jump Turn into More Strength?

Astronics and Boston Beer have been highlighted as Zacks Bull and Bear of the Day

Will Trump Tariffs Make or Break Healthcare Space? 3 Stocks to Rely On

5 Biotech Stocks Worth Adding Amid Global Uncertainty in 2025

3 Reasons Why Growth Investors Shouldn't Overlook BioMarin (BMRN)

What Makes BioMarin (BMRN) a New Buy Stock

BMRN vs. CSLLY: Which Stock Is the Better Value Option?

Are You a Value Investor? This 1 Stock Could Be the Perfect Pick

Spotting Winners: United Therapeutics (NASDAQ:UTHR) And Therapeutics Stocks In Q4

BMRN's PKU Drug Palynziq Meets Goal in Late-Stage Pediatric Study

Q4 Earnings Outperformers: Amgen (NASDAQ:AMGN) And The Rest Of The Therapeutics Stocks

BioMarin’s trial for phenylketonuria therapy meets primary efficacy endpoint

Performance Overview